

Small diagnostic biopsies

Handling and reporting issues

Dr Varsha Shah

Consultant Histopathologist

Royal Gwent Hospital

Newport

Biopsy vs. resection specimens

Smaller Tissues: **Larger Issues**

Biopsy pathology

Differences from resection pathology

Smaller Tissues: **Larger Issues**


- **Interpretation** issues
- **Sampling** issues
- **Handling** issues
- **Time** constraints
- **Clinical** implications

Small biopsies

Interpretation issues

- Limited material
- Fragmented material
- Uncertain topography
- Background

Who is this?



Who is this?




Who is this?




Interpretation issue

- **Very familiar obvious diagnosis difficult on limited material**


Endometrial bx



Endometrial bx




Endometrioid adenocarcinoma



Interpretation issue

- **Very familiar obvious diagnosis difficult on limited material**
 - However, sometimes even limited material may be diagnostic


Endometrial biopsy



Endometrial biopsy



“Snake in the grass”





Interpretation issue


- Very familiar obvious diagnosis difficult on limited material
- Less familiar diagnosis may be difficult even with more generous material
- Diagnosis is more difficult in fragmented specimens

Fragmented material

?????




Re-bx: Endometrioid adenocarcinoma




Interpretation issue

- Very familiar obvious diagnosis difficult on limited material
- Less familiar diagnosis may be difficult even with more generous material
- Diagnosis is more difficult in fragmented specimens
- Experts may be able to suspect diagnosis on limited material from rare tumours

Endometrial bx: **PMB**




Corded and hyalinised variant of endometrioid ca (CHEC)




Interpretation issue

- Very familiar obvious diagnosis difficult on limited material
- Less familiar diagnosis may be difficult even with more generous material
- Diagnosis is more difficult in fragmented specimens
- Experts may be able to suspect diagnosis on limited material from rare tumours
- **Even experts cannot make diagnosis on identical mimics**



Vertebral body biopsy

Metastatic follicular carcinoma




Interpretation issues

- Limited material
- Fragmented material
- **Uncertain topography**
- Background


Perimenopausal bleeding

Endometrial bx




Perimenopausal bleeding

Endometrial bx




Perimenopausal bleeding

Endometrial bx




Perimenopausal bleeding



Endometrial bx





Endometrial biopsy



Endometrial biopsy



Endometrioid adenocarcinoma with squamous morules




Identification more difficult

- Limited material from a familiar tumour
 - Especially less diagnostic area
- Unfamiliar tumour even with more generous material
- Morphological mimic
- Uncertain location


Small biopsies

Interpretation issues




- Limited material
- Fragmented material
- Uncertain topography
- **Background**



Atrophic endometrial polyp




“Right background”




“Right background”

p53



p16





FAN - TV Premiere

0m



Sunday, 7.19pm

1h 25m



FAN - TV Premiere


0m






1h 25m

Sunday, 7.19pm

Misleading background



Misleading background






Smaller Tissues: **Larger Issues**


- Interpretation issues
- **Sampling issues**
- Handling issues
- Time constraints
- Clinical implications

Endometrial bx


- **Luminal component sampled by bx may not be representative**
 - Myoinvasive component may be of different grade




Mixed carcinomas



EC with Serous



EC with Clear cell




EC with Chorio



Biopsy issue






- Tumour heterogeneity

Morphological heterogeneity



Clonal heterogeneity






Tumour heterogeneity

- **Tumours are genetically heterogeneous**
 - Each tumour is composed of multiple clones that may have very different outcomes


Biopsy limitations

- Tumours are genetically heterogeneous
- ALL tests can tell us only about the bit of cancer studied



Biopsy limitations


- Tumours are genetically heterogeneous
- ALL tests can tell us only about the bit of cancer studied
 - Not about the rest of the tumour



Biopsy limitations



- Tumours are genetically heterogeneous
- ALL tests can tell us only about the bit of cancer studied
 - Not about the rest of the tumour
 - Only about **present** morphology and genetic makeup

Endometrial cancer hysterectomy



Hysterectomy

Vaginal recurrence
10 yrs later



Biopsy limitations

- Information only about **that part** of tumour
at **that time**

Smaller Tissues: **Larger Issues**

- Interpretation issues
- Sampling issues
- **Time constraints**
- Clinical implications
- Handling issues

Time constraints

■ Bx TAT

- Clinically important
- Cancer targets!

■ Resection TAT

- Clinically less urgent – patient has to recover before adjuvant Rx
- “Clock stopped” after surgery

Smaller Tissues: **Larger Issues**

- Interpretation issues
- Sampling issues
- Time constraints
- **Clinical implications**
- Handling issues

Biopsy vs. resection specimens

Clinical implications

- **Biopsy data guides immediate management**
 - Provides only estimate of grade/extent ...
 - But may guide type/extent of surgery

Biopsy vs. resection specimens

Clinical implications

- Biopsy data guides immediate management
 - Provides only estimate of grade/extent ...
 - But may guide type/extent of surgery
- **Resection data is “The Final Diagnosis”**
 - Definitive data for prognostication and adjuvant therapy

Biopsy pathology

Differences from resection pathology

- **Different clinical requirements**
 - Critical for pathologists to be aware how path data used in that particular case

Bx: Endometrial carcinoma

- **Critical**

- Low-grade vs. High-grade

Bx: Endometrial carcinoma

- **Critical**

- Low-grade vs. High-grade

- **Important**

- G3 EC vs. Serous

Bx: Endometrial carcinoma

- **Critical**

- Low-grade vs high-grade

- **Important**

- G3 EC vs. Serous

- **Unimportant**

- Serous vs. Clear cell vs. Carcinosarcoma

Smaller Tissues: **Larger Issues**


- Interpretation issues
- Sampling issues
- Time constraints
- Clinical implications
- **Handling issues**

Handling biopsies

Cut-up bench

Don't put too much curettings in each cassette

- Fragments in deeper level may be from different part of endometrium



Biopsy pathology



Differences from resection pathology

- **Less tissue for morphology/IHC**
 - Taking extra blocks not an option

Biopsy pathology

Differences from resection pathology

- **Less tissue for morphology/IHC**
 - Taking extra blocks not an option
 - However, deeper levels is an option



Handling biopsies

Cut-up bench

- Don't put too much curettings in each cassette
 - Fragments in deeper level may be from different part of endometrium
- **Consider embedding core biopsies in multiple cassettes**

Core biopsy handling



Core biopsy handling



Handling biopsies

Cut-up bench: Macro

Handling biopsies

Cut-up bench: Macro

- **Must record number of pieces in each block (esp when <5):** Request levels if fewer in block
- **Max. dimension of each (or range) is sufficient**
 - No need to measure each bx in 3 dimensions
 - Only 2 dimensions seen on slide
- **Detailed macroscopic description (colour, consistency etc) is of limited clinical value**

Handling biopsies

Cut-up bench: Macro

MACRO:

Mole, neck. Two skin shaves the largest measuring 10 x 5 x 2 mm with a grey surface smaller piece measuring 6 x 4 x 2 mm with a grey surface, larger piece sliced in to three. A1, AE.

Fixation issue

- Formalin *permeation time* is 1mm/hour
- Tissue does **NOT** fix at 1mm/hr
- Fixation requires cross linking of proteins
- Cross-linking of proteins takes much longer
- Optimal fixation: 8 – 24 hours

Fixation issue

- **Small biopsies may need as long fixation time as larger tissue blocks**

Fixation issue

- **Small biopsies may need as long fixation time as larger tissue blocks**
 - Recent study suggests that shorter fixation time may not affect ER immunostaining

Fixation issue

- Small biopsies may need as long fixation time as larger tissue blocks
 - Recent study suggests that shorter fixation time may not affect ER immunostaining
- **Under-fixation causes more problems than over-fixation**

Reporting biopsies

Immunohistochemistry

- **Blunderbuss approach not recommended**
 - Wasteful
 - Often yields confusing results
 - May exhaust tissue

Reporting biopsies



Immunohistochemistry

- Blunderbuss approach not recommended
- **Size of immunopanel should depend on:**
 - Clinical scenario
 - Morphological differential diagnosis
 - Degree of uncertainty
 - Significance of differential diagnosis

Handling



BlueCoat +



Reporting biopsies

Immunohistochemistry

- If multiple immunostains likely then consider melting block and dividing material into multiple blocks

Core biopsy handling

Immunohistochemistry

■ Option A

- Serial or deeper sections cut upfront
- H&E on first and last section
- Rest retained for immunohistochemistry
 - Only 1 spare on each slide to avoid tissue waste

■ Option B

- 1 section with minimum trimming
- If non-diagnostic:
 - 3 levels + immuno spares based on DD

Reporting biopsies

Immunohistochemistry

- **Try not to exhaust block**
 - Retain some material for IHC/molecular testing in future (may be several years later)

Thank You

